PubMed 5 Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadela

PubMed 5. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M: Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998,188(4):619–626.PubMedCrossRef 6. Yu K, Hu Y, Tan Y, Shen Z, Jiang S, Qian H, Liang B, Shan D: Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma 2008,49(7):1368–1373.PubMedCrossRef

7. Van Meerten T, Hagenbeek A: CD20-targeted click here therapy: a breakthrough in the treatment of non-Hodgkin’s lymphoma. Neth J Med 2009,67(7):251–259.PubMed 8. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003,22(47):7359–7368.PubMedCrossRef 9. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al.: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008,359(22):2313–2323.PubMedCrossRef 10. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003,101(11):4279–4284.PubMedCrossRef 11. Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, AG-881 Olivares

S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL: Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006, 8:105–117.PubMedCrossRef 12. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D,

Ghebremichael M, et al.: Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother 2010, 33:155–166.PubMedCrossRef 13. Wall L, Burke F, Barton C, Smyth J, Balkwill F: IFN-gamma induces PTK6 apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 2003,9(7):2487–2496.PubMed 14. Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K: Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol 1983,130(2):988–992.PubMed 15. Maraskovsky E, Chen WF, Shortman K: IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989,143(4):1210–1214.PubMed 16. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005,435(7042):677–681.PubMedCrossRef 17. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002,99(3):1038–1043.PubMedCrossRef selleck chemicals llc competing interests The authors declare that they have no competing interests.

Comments are closed.